title: Detection of peptide-specific cytotoxic T-lymphocyte precursors used for specific immunotherapy of pancreatic cancer.
abstract: The prognosis of pancreatic cancer is extremely poor with a 5-year survival of approximately 3%. Thus, the development of new treatment modalities, including a specific immunotherapy, is required. Our study investigated whether cytotoxic T-lymphocyte (CTL) precursors reacting to peptides with vaccine candidates (13 peptides for HLA-A2+ or -A24+ patients, respectively) were detectable in the prevaccination peripheral blood mononuclear cells (PBMCs) of 15 pancreatic cancer patients. Peptide-specific CTL precursors were detectable in the majority (11 of 15, 73%) of patients, with a mean positive number of 1.5 peptides (ranging from 0-5 peptides) per patient. Positive peptide profiles varied among patients. These results may provide a scientific basis for a new kind of cancer immunotherapy, namely, a CTL precursor-oriented peptide vaccine, for pancreatic cancer patients.
authors.affiliation: Department of Immunology, Kurume University School of Medicine, Fukuoka, Japan.
authors.forename: Nobuaki
authors.initials: N
authors.lastname: Suzuki
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Maeda
authors.forename: Shoko
authors.initials: S
authors.lastname: Tanaka
authors.forename: Naoya
authors.initials: N
authors.lastname: Hida
authors.forename: Takashi
authors.initials: T
authors.lastname: Mine
authors.forename: Koutaro
authors.initials: K
authors.lastname: Yamamoto
authors.forename: Masaaki
authors.initials: M
authors.lastname: Oka
authors.forename: Kyogo
authors.initials: K
authors.lastname: Itoh
mesh_terms: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines / Q000276:immunology; D004268:DNA-Binding Proteins; D015234:HLA-A Antigens / Q000032:analysis*; D015789:HLA-A2 Antigen / Q000032:analysis*; D059871:HLA-A24 Antigen; D006412:Hematopoietic Stem Cells / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy; D009363:Neoplasm Proteins; D010190:Pancreatic Neoplasms / Q000276:immunology* / Q000628:therapy; D016601:RNA-Binding Proteins; D017411:Ribonucleoproteins, Small Nuclear; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D004268:DNA-Binding Proteins; D015234:HLA-A Antigens; D015789:HLA-A2 Antigen; D059871:HLA-A24 Antigen; D009363:Neoplasm Proteins; D016601:RNA-Binding Proteins; D017411:Ribonucleoproteins, Small Nuclear; C431323:SART1 protein, human; C416530:SART3 protein, human; C405383:DSE protein, human